SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-23-007377
Filing Date
2023-12-01
Accepted
2023-12-01 07:37:06
Documents
12
Period of Report
2023-11-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_113023.htm   iXBRL 8-K 19497
  Complete submission text file 0001171843-23-007377.txt   191261

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bcrx-20231128.xsd EX-101.SCH 3030
3 XBRL LABEL FILE bcrx-20231128_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE bcrx-20231128_pre.xml EX-101.PRE 22369
6 EXTRACTED XBRL INSTANCE DOCUMENT f8k_113023_htm.xml XML 3294
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 231457550
SIC: 2836 Biological Products, (No Diagnostic Substances)